Aurinia settles Lupkynis patent litigation with Teva

Regulation
โดย Seeking Alpha·US·Read original
Summary · why it matters

Aurinia Pharmaceuticals has settled patent litigation with Teva Pharmaceutical Industries over Lupkynis, delaying any generic version of the drug until December 7, 2036, at the earliest. Teva had filed an Abbreviated New Drug Application to sell generic voclosporin, the active ingredient in Lupkynis. Aurinia still faces patent litigation against several other generic companies seeking to market generic voclosporin.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
Aurinia Pharmaceuticals Inc
AUPH
▲ PositiveRegulationrelevance

Settlement with Teva delays generic Lupkynis until 2036, protecting Aurinia's market exclusivity.

Health Care▲ · 1 stocks
© 2026 MarketDXNews